Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Advanced Solid Tumors · Agitation Associated with Alzheimer’s Disease

Bristol-Myers Squibb Australia

Bristol-Myers Squibb Australia Pty Ltd

Bristol-Myers Squibb Australia clinical programs — 93 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
PO Box 1080, Mount Waverley, Victoria 3149, Australia HQ
6 Employees
TGA registrant Type
Company details
Status
Public
HQ
PO Box 1080, Mount Waverley, Victoria 3149, Australia
Employees
6
Programs
93
Drugs
120
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Bristol-Myers Squibb Australia projects

93 ClinicalTrials.gov programs sponsored by Bristol-Myers Squibb Australia.

Bristol-Myers Squibb Australia has 93 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

93 programs

Clinical programs

Page 1 of 2

  1. BMS-986353

    Bristol-Myers Squibb Australia Pty Ltd

    Systemic Sclerosis

    phase 3 small molecule active

    1 trial

  2. CA017-078

    Bristol-Myers Squibb Australia Pty Ltd

    Bladder Cancer Muscle-Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  3. CA127-1030

    Bristol-Myers Squibb Australia Pty Ltd

    Non small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  4. CA209-577

    Bristol-Myers Squibb Australia Pty Ltd

    Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer

    phase 3 small molecule active

    1 trial

  5. CA209-67T

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  6. CA209-8HW

    Bristol-Myers Squibb Australia Pty Ltd

    Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)

    phase 3 small molecule active

    1 trial

  7. CA209-8Y8

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors

    phase 3 small molecule active

    1 trial

  8. CA209-901

    Bristol-Myers Squibb Australia Pty Ltd

    Untreated Unresectable or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

  9. CA209-9DW

    Bristol-Myers Squibb Australia Pty Ltd

    Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  10. CA209-9DX

    Bristol-Myers Squibb Australia Pty Ltd

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  11. CA209-9ER

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or Metastatic Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  12. CA209-9LA

    Bristol-Myers Squibb Australia Pty Ltd

    Stage IV Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  13. CA224-047

    Bristol-Myers Squibb Australia Pty Ltd

    Previously Untreated Metastatic or Unresectable Melanoma

    phase 3 small molecule active

    1 trial

  14. CA224-098

    Bristol-Myers Squibb Australia Pty Ltd

    Participants with completely resected Stage III or Stage IV melanoma

    phase 3 small molecule active

    1 trial

  15. CA224-123

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  16. CA2241093

    Bristol-Myers Squibb Australia Pty Ltd

    Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  17. CA239-0004

    Bristol-Myers Squibb Australia Pty Ltd

    Locally Advanced or Metastatic Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  18. CA240-0029

    Bristol-Myers Squibb Australia Pty Ltd

    metastatic non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  19. CA240-0030

    Bristol-Myers Squibb Australia Pty Ltd

    Untreated Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  20. CA244-0008

    Bristol-Myers Squibb Australia Pty Ltd

    Breast cancer, Triple-negative breast cancer

    phase 3 small molecule active

    1 trial

  21. CA244-0010

    Bristol-Myers Squibb Australia Pty Ltd

    EGFR-mutated Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  22. CA2440012

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  23. CA245-0001

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  24. CA2660001

    Bristol-Myers Squibb Australia Pty Ltd

    Unresectable Stage III non-small cell lung cancer without progression

    phase 3 small molecule active

    1 trial

  25. CA2660002

    Bristol-Myers Squibb Australia Pty Ltd

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  26. CA2660003

    Bristol-Myers Squibb Australia Pty Ltd

    Untreated, Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  27. CA2660004

    Bristol-Myers Squibb Australia Pty Ltd

    Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  28. CN012-0023

    Bristol-Myers Squibb Australia Pty Ltd

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  29. CN012-0024

    Bristol-Myers Squibb Australia Pty Ltd

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  30. CN012-0025

    Bristol-Myers Squibb Australia Pty Ltd

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  31. CN012-0036

    Bristol-Myers Squibb Australia Pty Ltd

    BP-I mania or mania with mixed features

    phase 3 small molecule active

    1 trial

  32. CN012-0037

    Bristol-Myers Squibb Australia Pty Ltd

    BP-I mania or mania with mixed features

    phase 3 small molecule active

    1 trial

  33. CN012-0038

    Bristol-Myers Squibb Australia Pty Ltd

    Mania or Mania with Mixed Features in Bipolar-I Disorder

    phase 3 small molecule active

    1 trial

  34. CN012-0046

    Bristol-Myers Squibb Australia Pty Ltd

    BP-I mania or mania with mixed features

    phase 3 small molecule active

    1 trial

  35. CN012-0051

    Bristol-Myers Squibb Australia Pty Ltd

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  36. CN012-0052

    Bristol-Myers Squibb Australia Pty Ltd

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  37. CN0120020

    Bristol-Myers Squibb Australia Pty Ltd

    Schizophrenia

    phase 3 small molecule active

    1 trial

  38. CN0120056

    Bristol-Myers Squibb Australia Pty Ltd

    Psychosis Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  39. CV027-010

    Bristol-Myers Squibb Australia Pty Ltd

    Symptomatic Obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  40. IM011-054

    Bristol-Myers Squibb Australia Pty Ltd

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  41. IM011-055

    Bristol-Myers Squibb Australia Pty Ltd

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  42. IM011-075

    Bristol-Myers Squibb Australia Pty Ltd

    Moderate-to-Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  43. IM011-1069

    Bristol-Myers Squibb Australia Pty Ltd

    Sjogren's syndrome

    phase 3 small molecule active

    1 trial

  44. IM011-1071

    Bristol-Myers Squibb Australia Pty Ltd

    Juvenile Psoriatic Arthritis (JPsA)

    phase 3 small molecule active

    1 trial

  45. IM011-1128

    Bristol-Myers Squibb Australia Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  46. IM027068

    Bristol-Myers Squibb Australia Pty Ltd

    Idiopathic pulmonary fibrosis

    phase 3 small molecule active

    1 trial

  47. IM0271015

    Bristol-Myers Squibb Australia Pty Ltd

    Progressive Pulmonary Fibrosis

    phase 3 small molecule active

    1 trial

  48. IM047-001

    Bristol-Myers Squibb Australia Pty Ltd

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Bristol-Myers Squibb Australia have?

93 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.